Vireo Growth Performance dei guadagni passati
Il passato criteri di controllo 0/6
Vireo Growth has been growing earnings at an average annual rate of 6.1%, while the Pharmaceuticals industry saw earnings growing at 46% annually. Revenues have been growing at an average rate of 23.7% per year.
Informazioni chiave
6.1%
Tasso di crescita degli utili
20.4%
Tasso di crescita dell'EPS
| Pharmaceuticals Crescita del settore | 23.1% |
| Tasso di crescita dei ricavi | 23.7% |
| Rendimento del capitale proprio | n/a |
| Margine netto | -17.5% |
| Prossimo aggiornamento sui guadagni | 13 Nov 2024 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Vireo Growth Inc.'s (CSE:VREO) 29% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Oct 12
Vireo Growth Inc. (CSE:VREO) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Aug 10Market Might Still Lack Some Conviction On Goodness Growth Holdings, Inc. (CSE:GDNS) Even After 30% Share Price Boost
Jun 01Goodness Growth Holdings, Inc. (CSE:GDNS) Stock Rockets 30% But Many Are Still Ignoring The Company
Apr 06Investors Still Aren't Entirely Convinced By Goodness Growth Holdings, Inc.'s (CSE:GDNS) Revenues Despite 59% Price Jump
Feb 01Goodness Growth Holdings (CSE:GDNS) Is Carrying A Fair Bit Of Debt
Dec 14Health Check: How Prudently Does Goodness Growth Holdings (CSE:GDNS) Use Debt?
Jul 14Is Vireo Health International (CSE:VREO) Weighed On By Its Debt Load?
Mar 19Did Business Growth Power Vireo Health International's (CSE:VREO) Share Price Gain of 127%?
Jan 25Ripartizione dei ricavi e delle spese
Come Vireo Growth guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
| Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 30 Jun 24 | 98 | -17 | 28 | 0 |
| 31 Mar 24 | 93 | -24 | 31 | 0 |
| 31 Dec 23 | 88 | -26 | 32 | 0 |
| 30 Sep 23 | 83 | -34 | 33 | 0 |
| 30 Jun 23 | 77 | -37 | 36 | 0 |
| 31 Mar 23 | 78 | -36 | 35 | 0 |
| 31 Dec 22 | 75 | -42 | 37 | 0 |
| 30 Sep 22 | 69 | -43 | 39 | 0 |
| 30 Jun 22 | 64 | -41 | 39 | 0 |
| 31 Mar 22 | 57 | -41 | 39 | 0 |
| 31 Dec 21 | 54 | -34 | 39 | 0 |
| 30 Sep 21 | 53 | -22 | 36 | 0 |
| 30 Jun 21 | 52 | -13 | 34 | 0 |
| 31 Mar 21 | 50 | -22 | 40 | 0 |
| 31 Dec 20 | 49 | -23 | 39 | 0 |
| 30 Sep 20 | 48 | -63 | 44 | 0 |
| 30 Jun 20 | 42 | -78 | 45 | 0 |
| 31 Mar 20 | 36 | -62 | 35 | 0 |
| 31 Dec 19 | 30 | -57 | 28 | 0 |
| 30 Sep 19 | 25 | -17 | 20 | 0 |
| 30 Jun 19 | 22 | -4 | 15 | 0 |
| 31 Mar 19 | 21 | -4 | 12 | 0 |
| 31 Dec 18 | 18 | -3 | 12 | 0 |
| 30 Sep 18 | 16 | -2 | 9 | 0 |
| 31 Dec 17 | 11 | 0 | 6 | 0 |
| 31 Dec 16 | 4 | 6 | 4 | 0 |
Guadagni di qualità: VREO is currently unprofitable.
Margine di profitto in crescita: VREO is currently unprofitable.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: VREO is unprofitable, but has reduced losses over the past 5 years at a rate of 6.1% per year.
Accelerare la crescita: Unable to compare VREO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Guadagni vs Settore: VREO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-40.8%).
Rendimento del capitale proprio
ROE elevato: VREO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.